In an ongoing search for cancer-preventing compounds derived from plant sources, we isolated the quinolin-2,4-dione alkaloid severibuxine from the root bark of Severinia buxifolia collected in Taiwan and then examined the apoptotic effect of this compound. Severibuxine showed cytotoxicity to leukemia HL-60 cells (IC 50 = 12.3±0.6 M). Fluorescence microscopic analysis of cells stained with Hoechst 33342 indicated that the percentage of apoptotic cells showing nuclear condensation and fragmentation increased in a time-dependent manner. In addition, the activities of caspase-9 and caspase-3 were also enhanced in a timedependent manner upon treatment with severibuxine. The addition of caspase-9 and caspase-3 inhibitors blocked severibuxine-mediated apoptosis. Upon treatment with severibuxine, the mitochondrial membrane potential decreased in a time-dependent manner. Severibuxine induced apoptosis in HL-60 cells through activation of the caspase-9/caspase-3 pathway, which is triggered by mitochondrial dysfunction.
A research focus of our laboratory is the analysis of the chemical constituents of plants of the Rutaceae family. We previously identified various compounds in Citrus, Murraya and Clausena, which are species used in folk medicine in China and other Asian countries [1] . Severinia buxifolia is a close relative of the genus Citrus. It is a wild thorny shrub claimed to be a useful folk medicine for the treatment of chronic rheumatism, paralysis, snake-bite and malaria [2] . We previously reported the isolation of several acridone alkaloids and sesquiterpenes from the root bark of S. buxifolia collected in Taiwan [3] [4] [5] . Several of these acridone alkaloids proved cytotoxic against a small panel of tumor cells [6] . During an initial screening for novel anti-tumor agents, we found that several acridone alkaloids potently inhibited Epstein-Barr virus early antigen (EBV-EA) activation induced by 12-Otetradecanoylphorbol-13-acetate (TPA) in Raji cells [7] .
We reported the isolation from S. buxifolia and structural elucidation of a novel quinolin-2,4-dione alkaloid having two geranyl groups at the C-3 position ( Figure 1 ). This compound, severibuxine, showed strong cytotoxic activity against P-388 [8] . The present paper demonstrates that severibuxine induces apoptotic cell death in human leukemia cell line HL-60.
We examined the effect of severibuxine (Figure 1 ) on the viability of human leukemia HL-60 cells. To assess cell viability, we used a CellTiter 96 Aqueous assay kit. This assay is based on the metabolic conversion by living cells of the MTS tetrazolium compound to a colored formazan product; the quantity of formazan product is directly proportional to the number of viable cells in the culture. As shown in Figure 2 , when HL-60 cells were exposed to severibuxine (30 M) for up to 24 h, cell viability gradually decreased in a time- dependent fashion to 32% of the control cells. Severibuxine showed cytotoxic activity against HL-60 cells with an IC 50 value of 12.3±0.6 M.
To determine whether severibuxine-induced loss of cell viability is due to apoptosis, we examined the nuclear morphology of HL-60 cells treated with severibuxine using Hoechst 33342 staining. As shown in Figure 3 increased in HL-60 cells exposed to severibuxine (30 M) in a time-dependent manner. No apoptotic nuclei were observed in the control untreated cells ( Figure 3 ). These results indicate that severibuxine induces apoptotic death in HL-60 cells.
It is widely accepted that the activation of caspases plays a critical role in the mechanism of apoptotic cell death [9] . The intrinsic apoptotic pathway is initiated by the release of cytochrome c from dysfunctional mitochondria. The released cytochrome c binds to and activates the adaptor protein Apaf-1, which in turn activates caspase-9. This leads to the formation of an apoptosome and subsequent activation of downstream caspases, such as caspase-3 [10] . To examine whether severibuxine induces apoptosis via the caspase-dependent pathway, we first examined the proteolytic activity of caspase-9 in cell lysates by assaying the cleavage of LEHD-AFC, a fluorescent substrate specific for caspase-9. As shown in Figure 4A , a time-dependent increase in caspase-9 activity was observed in severibuxine-treated cells. Then, the activity of caspase-3, which is activated downstream of caspase-9, was fluorometrically assayed using the fluorogenic substrate DEVD-AFC after treatment with severibuxine ( Figure 4B ). The activity of caspase-3 time-dependently increased in severibuxine-treated cells, in a manner similar to that seen for caspase-9 activation ( Figures 4A  and B ).
To determine whether the activation of intracellular caspase-9 and caspase-3 is required for the induction of apoptosis by severibuxine, we examined the ability of specific caspase-9 and -3 inhibitors to prevent severibuxine-induced apoptosis. As shown in Figure 5 , the caspase-9 inhibitor Z-LEHD-FMK and caspase-3 inhibitor Z-DEVD-FMK effectively blocked the severibuxine-induced increase in apoptotic nuclei. Since caspase-9 and -3 inhibitors protected HL-60 cells from severibuxine-mediated apoptosis, it is possible that severibuxine induces apoptosis in HL-60 cells via caspase-9 and caspase-3 activation.
Mitochondrial dysfunction has been shown to lead to activation of the caspase-9 and -3 pathways [11] . Based on our observation that severibuxine induced caspase-9/3-mediated apoptosis, we evaluated the disruption of mitochondrial membrane potential. Using the JC-1 dye, we observed that severibuxine treatment resulted in a significant time-dependent loss of mitochondrial membrane potential; dose-dependent reduction of JC-1 aggregates is indicated by decreased ratios of red/green fluorescence intensity ( Figure 6 ). This result provides evidence that severibuxine induces loss of mitochondria membrane potential, initiating the mitochondrial dysfunction-mediated early cellular apoptosis pathway. Thus, it is possible that the apoptotic effect of severibuxine is mediated through mitochondrial dysfunction. It has been reported that mitochondrial dysfunction-mediated apoptosis involves various intracellular steps, including death receptor signaling [9] and DNA damage [12] . A study to identify the intracellular target site of severibuxine is currently in progress in our laboratory.
In conclusion, severibuxine, isolated from the root of S. buxifolia, induces apoptosis in HL-60 cells, and the apoptotic effects of severibuxine are mediated through the activation of caspase-9 and caspase-3. These findings suggest that severibuxine is a possible candidate for development as an anti-tumor agent.
Cytotoxic activity of severibuxine
Natural Product Communications Vol. 8 (6) 2013 777 Experimental Plant material: The plant material used in this study, S. buxifolia (Rutaceae), was collected from Tainan, Taiwan, and was identified by Professor Kuoh. A voucher specimen (NCKU-WU-810405) was deposited in the Herbarium of National Cheng Kung University, Tainan. The extraction and separation procedures used were reported previously [8] . Purity was corroborated by measurements of melting point, IR, UV and 1 H NMR spectra.
Cell culture and treatments:
The human leukemia cell line HL-60 was provided by the Cell Resource Center for Biomedical Research, Tohoku University (Sendai, Miyagi, Japan). Cells were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum in a humidified atmosphere of 5% CO 2 and 95% air at 37 o C. Severibuxine dissolved in dimethyl sulfoxide (DMSO) was added to the culture medium to give a final DMSO concentration of 0.5%. This concentration of DMSO had no significant effect on HL-60 cell viability (data not shown).
Assay of cell viability/cell growth:
Cell viability was determined using a CellTiter 96 Aqueous Assay kit (Promega, Madison, WI, USA). Cells were seeded in 96-well plates at a density of 1 x 10 5 cells per well. The cells were maintained for 24 h at 37 0 C, and then severibuxine (30 M) was added to the culture medium. MTS solution was added to the 96-well plates at the time points indicated in the figures, and the cells were incubated for 1 h at 37 o C. The absorbance was measured at 490 nm using a Wallac 1420 ARVOsx microplate counter (Applied Biosystems, Foster City, CA, USA).
Assessment of the percentage of apoptotic cells:
To detect apoptotic cells, cells were stained with DNA binding dye Hoechst 33342 (Dojindo, Kumamoto, Japan). After the cells were exposed to severibuxine for the desired period, they were fixed with 2% paraformaldehyde in phosphate-buffered saline (PBS) for 10 min at 4 o C, and were then washed with PBS. To stain the nuclei, cells were incubated for 20 min with 20g/mL Hoechst 33342. After washing with PBS, the cells were observed under a fluorescence microscope (Zeiss Axiophoto 2; Carl Zeiss, Oberkovhen, Germany). Cells exhibiting condensed and fragmented nuclei were scored as being apoptotic. A minimum of 200 cells was scored from each sample.
Measurement of enzyme activities of caspase-3 and caspase-9:
The enzyme activities of caspase-3 and caspase-9 were measured using a caspase fluorometric assay kit (R&D Systems Inc., Minneapolis, MN, USA). Cells were seeded in 24-well plates at a density of 3 x 10 6 cells per well. After exposure of the cells to 30M severibuxine for the desired period, the cells were washed 3 times with PBS and lysed in lysis buffer for 10 min on ice. The protein content of the cell lysates was assayed with a Micro BCA reagent (Pierce, Rockford, IL, USA). Cell lysates containing 50 g of protein were incubated with either caspase-9 fluorogenic substrate (LEHD-AFC) or caspase-3 fluorogenic substrate (DEVD-AFC) for 1 h at 37 o C. Caspase activity was measured by fluorometric detection using a Wallac 1420 ARVOsx microplate counter (excitation at 400 nm, emission at 505 nm; Applied Biosystems).
Caspase inhibition assay:
The caspase-9-specific inhibitor Z-LEHD-FMK (R&D Systems Inc.) and the caspase-3-specific inhibitor Z-DEVD-FMK (R&D Systems Inc.) were dissolved in DMSO. Cells were pretreated in differentiation media supplemented with either 50 M caspase inhibitor or DMSO as a control for 2 h at 37 o C, and then treated with 30 M severibuxine for 18 h at 37 o C. The number of apoptotic cells was determined by using the Hoechst 33342 staining.
Assay of mitochondrial membrane potential:
After treatment, cells were incubated for 15 min at 37 o C in RPMI-1640 medium containing 5g/mL JC-1 dye (Invitrogen, Carlsbad, CA). Cells were washed 3 times with PBS and then transferred to black 96-well plates. The JC-1 dye localizes within the mitochondria in proportion to membrane potential and forms aggregates that fluoresce red (excitation 550 nm; emission 600 nm). When membrane potential dissipates, the JC-1 dye leaks into the cytoplasm and fluoresces green (excitation 485 nm; emission 535 nm). The red and green fluorescence intensity was determined in a microplatefluorimeter (ImageXpress, Molecular Devices, Sunnyvale, CA). The mitochondrial membrane potential normalized to the number of cells was calculated by dividing mitochondrial red fluorescence by cytosolic green fluorescence.
Statistical analysis:
Statistical analysis was performed with SPSS version 10.0J for Windows (SPSS Inc., Chicago, IL, USA), using the Kruskal-Wallis test, and individual differences were examined by the Mann-Whitney U-test (Figures 2, 3, 4 and 6) . Differences between the 2 groups ( Figure 5 ) were statistically examined using the Mann-Whitney U-test. P < 0.05 denoted significance in all cases.
